Understanding the benefits of riboflavin

**Professor Mary Ward introduces the DERIVE project, which is developing accessible riboflavin biomarkers for use in population studies globally, in order to investigate and address the functional and health consequences of sub-optimal riboflavin status**

Can you explain the importance of riboflavin? Can you expand on the importance of riboflavin? Can you explain the benefits of good riboflavin status? What do you hope to achieve in relation to patients suffering from hypertension? What is the ultimate goal for both the DERIVE and VALID projects? Can you expand on your work with Professor Ward? Could you begin by introducing yourself and your key research interests? Could you begin by introducing yourself and your research interests?

**Riboflavin (vitamin B2) is a water-soluble B-vitamin that forms two important co-enzymes – flavin mononucleotide (FMN) and flavin dinucleotide (FAD). Further to its well established role in health, recent novel work undertaken by our team at Ulster demonstrated that riboflavin plays a critical role in normalising blood pressure in people with the TT genotype in the gene encoding MTHFR.**

**Previous work at Ulster has led to the novel discovery that the B-vitamin riboflavin appears to be an important modulator of blood pressure in individuals with this genetic predisposition for hypertension. Our current studies aim to understand the mechanisms linking this gene nutrient interaction with blood pressure.**

**Our Canadian partner from the University of British Columbia in Vancouver is developing accessible biomarkers for the assessment of riboflavin status. These will then be validated by measuring biomarker status in biological samples from nationally representative cohorts in Ireland and Canada, and samples from randomised controlled trials completed at Ulster. Their reliability as biomarkers of dietary intake will be determined using data from the Irish National Adult Nutrition Survey cohort led by our partners from University College Cork in Ireland.**

**What do you hope to achieve in relation to patients suffering from hypertension?**

The health impact of optimising riboflavin could be considerable. For hypertensive patients identified with the TT genotype, riboflavin supplementation can offer a simple, non-drug treatment to effectively lower blood pressure. For sub-populations worldwide with this genetic risk factor, better riboflavin status (achieved through supplements or fortified foods) may prevent or delay the onset of high blood pressure. Thus, riboflavin, targeted at those with the TT genotype in MTHFR, offers a personalised treatment or preventative strategy for hypertension, one of the leading causes of mortality worldwide. High blood pressure (hypertension) has a number of adverse health consequences, in particular, it increases a person’s risk of stroke substantially. Lowering blood pressure has important health benefits: each 2mmHg decrease in systolic blood pressure is associated with a 10 per cent reduction in the risk of stroke. Thus, lowering blood pressure even by small amounts can be very beneficial.

**Polyphenols for healthier ageing**

**Via the VALID project, Professor Helene McNulty is validating novel plasma biomarkers of polyphenol-rich foods and linking them with inflammation, metabolic health and cognition in an ageing European population.**

**Polyphenols are among the most representative bioactive compounds, mainly present in plant-based foods – particularly grapes, nuts, berries, wine, tea and coffee. Polyphenols are not included in the category of micronutrients, as they are not essential for the maintenance of vital functions. However, several epidemiological and intervention studies show beneficial associations between long term intake of polyphenols and reduced incidence of cancer, chronic diseases and neurodegenerative processes.**

In collaboration with experts in polyphenol biomarker analysis from the University of Parma, Italy, and our TUDA collaborators in Trinity College Dublin, the VALID project will identify and validate plasma-valerolactones as novel biomarkers that are modulated by dietary polyphenols and associated with cognitive function in later life.

**What is the ultimate goal for both the DERIVE and VALID projects?**

The vision and goal of both the DERIVE and VALID projects is to promote scientific excellence through international collaboration across centres of excellence, which are allowing the collection and pooling of nutrition and health data in a uniform and standardised way. Furthermore, the sharing of expertise from across the participating countries allows cross-border mobility and training of researchers and will facilitate the timely dissemination and translation of our research results to inform public health practice and policy across Europe, and indeed globally.

**Project Insights**

**FUNDING**

DERIVE funding: at Ulster University – BB/PS02471/1, at University College Cork – Science Foundation Ireland, 16/E/HDHL/3732 and at the University of British Columbia by the Canadian Institutes of Health Research – OBI-150362.

VALID funding: at Ulster University – BB/PS02471/1, at Trinity College Dublin – Science Foundation Ireland, 16/E/HDHL/3732; and at University of Parma: Ministero delle Politiche Agricole Alimentari e Forestali (MIPAAF) – D.M.3156.779/16 del 29/12/2016.

**DERIVE PROJECT INVESTIGATORS**

Prof Mary Ward (PI), Prof Helena McNulty, Prof Kristvika Penteiva, Prof Sean Strain, Dr Liamaddn McNen, Dr Paul Millar and Harry Jarrett (PhD researcher) – Ulster University, UK • Prof Albert Flynn, Dr Janette Walton and Laura Kelso (PhD researcher) – University College Cork, Ireland • Dr Yvonne Lamers, Prof John Spinelli, Dr Angela Devin and Dr Nadia Moran – University of British Columbia, Canada

**VALID PROJECT INVESTIGATORS**

Prof Helene McNulty (PI), Dr Chris Coll, Prof Mary Ward, Prof Sean Strain, Prof Adrian Moore, Dr Katie Moore, Dr Kieran westley, Ben Parameter (PhD researcher) and Bruna Pucci (PhD researcher) – Ulster University, UK • Prof Anne Molloy, Prof Conal Cunningham, Dr Eamon Laird, Dr Kevin McCarthy, Kerrie boyle (PhD researcher) and Brian Mullen (MRes Researcher) – Trinity College Dublin, Ireland • Prof Daniele Del Rio, Dr Donata Angelino and Dr Pedro mena – University of Parma, Italy

**CONTACT DETAILS**

Mary Ward and Helene McNulty Project Coordinators

T: +44 2807212096; +44 2807212483
E: m.ward@ulster.ac.uk; h.mcnulty@ ulster.ac.uk
W: www.ulster.ac.uk/niche; http://derive- riboflavin.com/research-project; www. jpi-valid.com; www.healthytodays life.eu/index.php/6-open-calls/311-derive Twitter: @Ulster_DERIVE; @validproject Twitter: https://twitter.com/DERIVE_Ulster https://twitter.com/NICHE_ULSTER

**Project Insights**

**FUNDING**

DERIVE funding: at Ulster University – BB/PS02471/1, at University College Cork – Science Foundation Ireland, 16/E/HDHL/3732 and at the University of British Columbia by the Canadian Institutes of Health Research – OBI-150362.

VALID funding: at Ulster University – BB/PS02471/1, at Trinity College Dublin – Science Foundation Ireland, 16/E/HDHL/3732; and at University of Parma: Ministero delle Politiche Agricole Alimentari e Forestali (MIPAAF) – D.M.3156.779/16 del 29/12/2016.

**DERIVE PROJECT INVESTIGATORS**

Prof Mary Ward (PI), Prof Helena McNulty, Prof Kristvika Penteiva, Prof Sean Strain, Dr Liamaddn McNen, Dr Paul Millar and Harry Jarrett (PhD researcher) – Ulster University, UK • Prof Albert Flynn, Dr Janette Walton and Laura Kelso (PhD researcher) – University College Cork, Ireland • Dr Yvonne Lamers, Prof John Spinelli, Dr Angela Devin and Dr Nadia Moran – University of British Columbia, Canada

**VALID PROJECT INVESTIGATORS**

Prof Helene McNulty (PI), Dr Chris Coll, Prof Mary Ward, Prof Sean Strain, Prof Adrian Moore, Dr Katie Moore, Dr Kieran westley, Ben Parameter (PhD researcher) and Bruna Pucci (PhD researcher) – Ulster University, UK • Prof Anne Molloy, Prof Conal Cunningham, Dr Eamon Laird, Dr Kevin McCarthy, Kerrie boyle (PhD researcher) and Brian Mullen (MRes Researcher) – Trinity College Dublin, Ireland • Prof Daniele Del Rio, Dr Donata Angelino and Dr Pedro mena – University of Parma, Italy

**CONTACT DETAILS**

Mary Ward and Helene McNulty Project Coordinators

T: +44 2807212096; +44 2807212483
E: m.ward@ulster.ac.uk; h.mcnulty@ ulster.ac.uk
W: www.ulster.ac.uk/niche; http://derive- riboflavin.com/research-project; www. jpi-valid.com; www.healthytodays life.eu/index.php/6-open-calls/311-derive Twitter: @Ulster_DERIVE; @validproject Twitter: https://twitter.com/DERIVE_Ulster https://twitter.com/NICHE_ULSTER
Impact Objectives

- Gain a better understanding of the role of nutrition in health by developing and validating novel biomarkers of dietary exposure in transnational research studies
- Grow capacity, capability and sustainable transnational partnerships in nutrition and health research, led by a UK partner in collaboration with partners in Canada, Republic of Ireland and Italy
- Demonstrate the functional and metabolic effects of optimal riboflavin status on cardiovascular health (DERiVE project), and of dietary polyphenols on the ageing brain (VALID project)

Nourishing nutrition and health research

Two innovative projects underway at Ulster University, Northern Ireland, are inextricably linked by their shared focus on improving nutrition with implications for health across the lifespan.

Nutrition is of the utmost importance, particularly given the phenomenon of ageing populations worldwide. The lack of validated nutritional biomarkers in some cases however, is hampering the ability of researchers to investigate the roles and health benefits of certain nutrients.

Two projects underway at Ulster University, Northern Ireland, headed up by Professors Mary Ward and Helene McNulty, respectively, are:

- Development of riboflavin biomarkers to relate dietary sources with status, gene-nutrient interactions and validated health effects in adult cohorts (DERiVE). Project partners: Ulster University (Lead Institution), University of British Columbia (Canada) and University College Cork (Ireland).
- Valerolactones and healthy ageing: Linking dietary factors, nutrient biomarkers, metabolic status and inflammation with cognition in older adults (VALID). Project partners: Ulster University (Lead Institution), Trinity College Dublin (Ireland) and University of Parma (Italy).

DERIVE AND VALID

The two projects are closely related and share similar goals, as Ward and McNulty explain: ‘By linking these projects, it is our intention to build capacity and capability in nutrition research and to extend the international collaborations made possible through this JPI initiative.’

The DERiVE project will develop accessible riboflavin biomarkers for use in population surveys globally, and demonstrate important functional, gene-nutrient and health effects of optimal riboflavin status.

The VALID project will validate novel biomarkers of polyphenol-rich foods and link them with inflammation, metabolic health and cognition in an ageing European population.

Both projects are in their first year and will conclude at the end of 2019.

HEALTH IMPACTS

The goal of DERiVE is to promote health and wellness in adults, with evidence that sub-optimal riboflavin status may be a much greater global health risk than is currently recognised. ‘Riboflavin has an important role in one-carbon metabolism where it interacts with other relevant nutrients (folic acid, vitamin B12 and vitamin B6),’ Ward explains. VALID will develop and evaluate novel biomarkers that reflect dietary intakes of polyphenols (abundant in foods such as tea, cocoa, grapes, nuts and berries). ‘Our research will also investigate the biological mechanisms that could link dietary polyphenols with cognitive health as people age,’ McNulty adds.

Indeed, both projects are concerned with health impacts on ageing populations, as the researchers explain: ‘There is an urgent need to identify public health nutrition strategies aimed at promoting better health throughout the lifecycle for healthy ageing. We are committed to generating the highest quality research to support evidence-based policies to meet the nutrition and health needs of older populations globally.’

GROWING TRANSNATIONAL LINKS

Both projects are progressing well and, looking ahead, Ward and McNulty hope to expand these research areas. ‘These projects have enabled us to develop strong international collaborations in nutrition and health and we aim to not only grow our capacity, but also the capabilities of the teams. It is also intrinsic that the transnational partnerships we are developing in Canada, the Republic of Ireland and Italy, are sustainable.’

The DERiVE and VALID projects are funded under the JPI Co-funded ERA-HDHL joint call ‘Biomarker for nutrition and health’. In line with the JPI’s ‘A healthy diet for a healthy life’ vision to support quality, translational, collaborative research, the goal of both projects is to promote scientific excellence through international collaborations. Go to: www.healthydietforhealthylife.eu/index.php/joint-actions/era-hdhl-ja